CBFB and acute myeloid leukemia: Thus, a total of 17 patients comprising 11 de novo cases and 6 therapy-related AML cases with fusion transcripts (PML-RARA, n=2; RUNX1-RUNX1T1, n=3; CBFb-MYH11, n=1) included only 1 (5.9%) positive case, versus 25/87 (28.7%) in the remaining group of patients (p=0.064).